Company Overview of Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases; and obesity, including obesity caused by genetic deficiencies in the MC4 pathway. Its portfolio includes relamorelin (RM-131), a ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes and other GI functional disorders; and RM-493, a melanocortin-4 (MC4) receptor agonist for the treatment of obesity and obesity caused by genetic deficiencies in the MC4 pathway. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is based in Boston, Massachusetts.
855 Boylston Street
Boston, MA 02116
Founded in 2008
Key Executives for Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Effective Pharmaceuticals, Inc.||United States|
|IPR Pharmaceuticals Inc.||United States|
|Merck Holdings Trust||United States|
|Psychiatric Genomics, Inc.||United States|
|Fincor Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Rhythm Pharmaceuticals, Inc., please visit www.rhythmtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.